English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background  Ovarian carcinomas presenting homologous recombination deficiency (HRD), which is observed in about 50% of cases, are more sensitive to platinum and PARP inhibitor therapies. Although platinum resistant disease has a low chance to be responsive to platinum-based chemotherapy, a set of patients is retreated with platinum and some of them are responsive. In this study, we evaluated copy number alterations, HR gene mutations and HR deficiency scores in ovarian cancer patients with prolonged platinum sensitivity.    Methods  In this retrospective study (2005 to 2014), we selected 31 patients with platinum resistant ovarian cancer retreated with platinum therapy. Copy number alterations and HR scores were evaluated using the OncoScan® FFPE platform in 15 cases. The mutational profile of 24 genes was investigated by targeted-NGS.    Results  The median values of the four HRD scores were higher in responders (LOH = 15, LST = 28, tAI = 33, CS = 84) compared with non-responders (LOH = 7.5, LST = 17.5, tAI = 23, CS = 47). Patients with high LOH, LST, tAI and CS scores had better response rates, although these differences were not statistically significant. Response rate to platinum retreatment was 22% in patients with  CCNE1  gains and 83.5% in patients with no  CCNE1  gains ( p  = 0.041). Furthermore, response rate was 54.5% in patients with  RB1  loss and 25% in patients without  RB1  loss ( p  = 0.569). Patients with  CCNE1  gains showed a worse progression free survival (PFS = 11.1 months vs 3.7 months;  p  = 0.008) and a shorter overall survival (OS = 39.3 months vs 7.1 months;  p  = 0.007) in comparison with patients with no  CCNE1  gains. Patients with  RB1  loss had better PFS (9.0 months vs 2.6 months;  p  = 0.093) and OS (27.4 months vs 3.6 months;  p  = 0.025) compared with cases with no  RB1  loss. Four tumor samples were  BRCA  mutated and tumor mutations were not associated with response to treatment.    Conclusions  HR deficiency was found in 60% of our cases and HRD medium values were higher in responders than in non-responders. Despite the small number of patients tested,  CCNE1  gain and  RB1  loss discriminate patients with tumors extremely sensitive to platinum retreatment.    Electronic supplementary material  The online version of this article (10.1186/s12885-019-5622-4) contains supplementary material, which is available to authorized users.

bmc cancer

Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes